RU2214418C2 - Аналоги glp-1 - Google Patents

Аналоги glp-1 Download PDF

Info

Publication number
RU2214418C2
RU2214418C2 RU2001118855/04A RU2001118855A RU2214418C2 RU 2214418 C2 RU2214418 C2 RU 2214418C2 RU 2001118855/04 A RU2001118855/04 A RU 2001118855/04A RU 2001118855 A RU2001118855 A RU 2001118855A RU 2214418 C2 RU2214418 C2 RU 2214418C2
Authority
RU
Russia
Prior art keywords
glp
analogs
peptide analogs
peptides
peptide
Prior art date
Application number
RU2001118855/04A
Other languages
English (en)
Other versions
RU2001118855A (ru
Inventor
Женг Ксин Донг
Original Assignee
Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26808753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2214418(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас filed Critical Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас
Publication of RU2001118855A publication Critical patent/RU2001118855A/ru
Application granted granted Critical
Publication of RU2214418C2 publication Critical patent/RU2214418C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)

Abstract

Изобретение относится к пептидным аналогам глюкагонподобного пептида-1 формулы
(R2R3)-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-А23-А24-А25-А26-А27-А28-А29-А30-А31-А32-А33-А34-А35-А36-А37-А38-А39-R1, значения радикалов указаны в формуле изобретения. Соединения обладают высокой GLP-1-подобной активностью и могут использоваться для лечения диабета, ожирения и других заболеваний, связанных с нарушением метаболизма GLP-1 в организме. Описаны также фармацевтические композиции, содержащие указанные пептидные аналоги. 2 с. и 10 з.п. ф-лы, 2 табл.

Description

Текст описания в факсимильном виде (см. графическую часть) Т Т Т Ти

Claims (1)

  1. Текст формулы в факсимильном виде (см. графическую часть)п
RU2001118855/04A 1998-12-07 1999-12-07 Аналоги glp-1 RU2214418C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20660198A 1998-12-07 1998-12-07
US11125598P 1998-12-07 1998-12-07
US09/206,601 1998-12-07
US60/111,255 1998-12-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2003112447/04A Division RU2288232C9 (ru) 1998-12-07 1999-12-07 Аналоги glp-1

Publications (2)

Publication Number Publication Date
RU2001118855A RU2001118855A (ru) 2003-06-27
RU2214418C2 true RU2214418C2 (ru) 2003-10-20

Family

ID=26808753

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2001118855/04A RU2214418C2 (ru) 1998-12-07 1999-12-07 Аналоги glp-1
RU2003112447/04A RU2288232C9 (ru) 1998-12-07 1999-12-07 Аналоги glp-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2003112447/04A RU2288232C9 (ru) 1998-12-07 1999-12-07 Аналоги glp-1

Country Status (23)

Country Link
US (5) US6903186B1 (ru)
EP (2) EP2322545A1 (ru)
JP (5) JP3702181B2 (ru)
KR (3) KR100511855B1 (ru)
CN (2) CN1495198A (ru)
AT (1) ATE282635T1 (ru)
AU (1) AU762012B2 (ru)
BR (1) BR9915961A (ru)
CA (1) CA2353574C (ru)
CZ (6) CZ295890B6 (ru)
DE (1) DE69922043T2 (ru)
ES (1) ES2230912T3 (ru)
HK (1) HK1037196A1 (ru)
HU (1) HUP0104574A3 (ru)
IL (2) IL143346A0 (ru)
NO (2) NO319128B1 (ru)
NZ (2) NZ511931A (ru)
PL (1) PL202367B1 (ru)
PT (1) PT1137667E (ru)
RU (2) RU2214418C2 (ru)
SG (1) SG125915A1 (ru)
TW (6) TWI352599B (ru)
WO (1) WO2000034331A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2445972C2 (ru) * 2006-12-29 2012-03-27 Ипсен Фарма С.А.С. Фармацевтические композиции glp-1

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9915961A (pt) 1998-12-07 2001-08-21 Sod Conseils Rech Applic Análogos de glp-1
HUP0104579A3 (en) 1998-12-07 2002-05-28 Univ Tulane Glp-1 analogues, pharmaceutical compositions comprising thereof and their use
US20030204063A1 (en) * 2000-08-02 2003-10-30 Denis Gravel Modified biological peptides with increased potency
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
DE60134251D1 (de) 2000-09-18 2008-07-10 Sanos Bioscience As Verwendung von glp-2-peptiden
EP2062593A3 (en) 2000-12-01 2011-08-17 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive peptide
GB0100196D0 (en) * 2001-01-04 2001-02-14 Anmat Technology Ltd Peptides
JP2005501058A (ja) * 2001-07-31 2005-01-13 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
KR20040054729A (ko) * 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7332819B2 (en) * 2002-01-09 2008-02-19 Micron Technology, Inc. Stacked die in die BGA package
US7067488B2 (en) * 2002-09-25 2006-06-27 Theratechnologies Inc. Modified GLP-1 peptides with increased biological potency
CA2502118A1 (en) * 2002-10-11 2004-05-06 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1 derivatives and transmicosal absorption preparations thereof
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP2067483A1 (en) * 2003-02-19 2009-06-10 Ipsen Pharma Analogues of GLP-1
CN102134577A (zh) * 2003-03-28 2011-07-27 独立行政法人农业生物资源研究所 高产重组蛋白的植物贮藏器官的生产方法以及新型重组蛋白
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
ES2375056T3 (es) 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
CN102940879B (zh) 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
CA2551039C (en) * 2003-12-16 2013-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogues of glp-1
AR047776A1 (es) * 2003-12-16 2006-02-22 Sod Conseils Rech Applic Composiciones farmaceuticas glp - 1
MXPA06006745A (es) * 2003-12-18 2006-08-18 Novo Nordisk As Compuestos glp-1 novedosos.
WO2005066207A1 (en) * 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CN101010339B (zh) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
EP1799710A2 (en) 2004-10-07 2007-06-27 Novo Nordisk A/S Protracted glp-1 compounds
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
EP2441460A1 (en) * 2005-06-30 2012-04-18 Ipsen Pharma GLP-1 pharmaceutical compositions
US20070004616A1 (en) * 2005-06-30 2007-01-04 Roland Cherif-Cheikh GLP-1 pharmaceutical compositions
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
EP2573111A1 (en) 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
CN101563364B (zh) * 2006-06-23 2014-04-02 霍夫曼-拉罗奇有限公司 促胰岛素肽合成
GB0612669D0 (en) * 2006-06-27 2006-08-09 Univ Leeds Biomarkers for preeclampsia
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
KR101247665B1 (ko) * 2006-12-29 2013-04-02 입센 파마 에스.에이.에스 Ｇｌｐ―１ 약학 조성물
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
AU2008244523B2 (en) * 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100256056A1 (en) * 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
CA2703113A1 (en) 2007-10-27 2009-04-30 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
RU2010128247A (ru) * 2007-12-11 2012-01-20 Ф.Хоффманн-Ля Рош Аг (Ch) Синтез инсулинотропных пептидов с помощью комбинированных твердофазных и растворных методик
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
SG192405A1 (en) * 2008-06-17 2013-08-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
CA2953975C (en) 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
CN102170895A (zh) * 2008-08-07 2011-08-31 益普生制药股份有限公司 葡萄糖依赖性促胰岛素多肽类似物
US9074014B2 (en) * 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
EP2915538A3 (en) * 2008-08-07 2015-10-14 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
AU2009280021B2 (en) * 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
TW201012829A (en) * 2008-09-22 2010-04-01 Ipsen Mfg Ireland Ltd Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
CN102292348B (zh) * 2008-12-15 2015-07-08 西兰制药公司 胰高血糖素类似物
KR20110126589A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
CA2747155A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
PL2370460T3 (pl) 2008-12-15 2014-09-30 Zealand Pharma As Analogi glukagonu
JP2012512903A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
EP4246522A3 (en) 2008-12-23 2023-11-08 Roche Diabetes Care GmbH Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
TWI504405B (zh) 2009-01-22 2015-10-21 Novo Nordisk Healthcare Ag 穩定的生長激素化合物
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
WO2010125079A2 (en) * 2009-05-01 2010-11-04 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
SG176858A1 (en) 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
US20120264685A1 (en) 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
BR112012018116B1 (pt) 2010-01-22 2022-06-21 Novo Nordisk Health Care Ag Conjugados de hormônio do crescimento com eficácia in vivo prolongada
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20130123460A1 (en) 2010-04-30 2013-05-16 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US20110313131A1 (en) 2010-06-21 2011-12-22 Christelle Carl Reversed phase hplc purification of a glp-1 analogue
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
AP2013006671A0 (en) * 2010-06-24 2013-01-31 Zealand Pharma As Glucagon analogues
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
BR112013014942B1 (pt) 2010-12-16 2020-01-28 Novo Nordisk As composições sólidas para administração, e seus usos
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2612278T3 (es) 2011-04-12 2017-05-16 Novo Nordisk A/S Derivados de GLP-1 doble-acilados
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR20140053991A (ko) 2011-07-18 2014-05-08 아츠 바이올로직스 에이/에스 장기간 작용하는 황체 형성 호르몬 (ｌｈ) 화합물
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
AR090937A1 (es) 2012-05-03 2014-12-17 Zealand Pharma As Compuestos agonista duales de gip-glp-1 y metodos para usarlos
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
KR101848303B1 (ko) 2012-07-10 2018-04-13 삼성전자주식회사 전력 전송을 제어하기 위한 방법 및 이를 위한 전력 송신기
CN109456400A (zh) 2012-07-23 2019-03-12 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
WO2014077802A1 (en) 2012-11-13 2014-05-22 Ipsen Pharma S.A.S. Purification method of a glp-1 analogue
WO2014077801A1 (en) 2012-11-13 2014-05-22 Ipsen Pharma S.A.S. Purification process for preparing highly pure taspoglutide
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
WO2014209886A1 (en) 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptid-1
CN103536907B (zh) * 2013-07-18 2015-10-21 上海交通大学医学院附属瑞金医院 利拉鲁肽在骨质疏松治疗药物中的应用
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PT3057984T (pt) 2013-10-17 2018-10-24 Boehringer Ingelheim Int Análogos de glucagon acilados
CN105849122B (zh) 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
SG10201805039UA (en) * 2013-12-13 2018-07-30 Medimmune Ltd Protease resistant peptides
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
ES2685987T3 (es) 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3985016A1 (en) 2014-10-29 2022-04-20 Zealand Pharma A/S Gip agonist compounds and methods
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN106554409B (zh) * 2015-09-30 2020-04-07 天津药物研究院有限公司 一种长效胰高血糖素样肽-1类似物及其应用
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
CA3064510A1 (en) 2017-05-31 2018-12-06 University Of Copenhagen Long-acting gip peptide analogues
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
MX2020009950A (es) * 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.
PL3774862T3 (pl) 2018-04-05 2022-10-03 Sun Pharmaceutical Industries Limited Nowe analogi glp-1
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
MX2021004185A (es) 2018-10-11 2021-09-08 Intarcia Therapeutics Inc Polipeptidos analogos de la amilina humana y sus metodos de uso.
CN109400695B (zh) 2018-10-31 2020-06-30 中南大学湘雅医院 一种多肽的修饰方法及应用
WO2020115049A1 (en) 2018-12-03 2020-06-11 Antag Therapeutics Aps Modified gip peptide analogues
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1539498A (en) 1925-05-26 And fifteen
ATE110083T1 (de) 1986-05-05 1994-09-15 Gen Hospital Corp Insulinotropes hormon.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
JP3262329B2 (ja) * 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス 糖尿病治療に有用なｇｌｐ―１アナログ
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
CA2243718A1 (en) 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA72181C2 (ru) * 1996-08-30 2005-02-15 Ново Нордіск А/С Translated By PlajПРОИЗВОДНЫЕ ГЛЮКАГОНООБРАЗНОГО ПЕПТИДА-1
UA65549C2 (ru) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Применение аналогов и производных glp-1 для периферического введения для борьбы с ожирением
AU5549998A (en) * 1997-01-24 1998-08-18 Novo Nordisk A/S Synthetic leader peptide sequences
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
HUP0104579A3 (en) 1998-12-07 2002-05-28 Univ Tulane Glp-1 analogues, pharmaceutical compositions comprising thereof and their use
BR9915961A (pt) * 1998-12-07 2001-08-21 Sod Conseils Rech Applic Análogos de glp-1
WO2001035988A1 (en) 1999-11-12 2001-05-25 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2445972C2 (ru) * 2006-12-29 2012-03-27 Ипсен Фарма С.А.С. Фармацевтические композиции glp-1

Also Published As

Publication number Publication date
US20050233969A1 (en) 2005-10-20
US20040018981A1 (en) 2004-01-29
CZ20011748A3 (cs) 2002-02-13
DE69922043T2 (de) 2005-11-24
JP2006151988A (ja) 2006-06-15
CN100540566C (zh) 2009-09-16
TW593338B (en) 2004-06-21
CZ295044B6 (cs) 2005-05-18
TW200803889A (en) 2008-01-16
JP4386887B2 (ja) 2009-12-16
HUP0104574A2 (hu) 2002-04-29
IL187907A0 (en) 2008-03-20
JP2008001710A (ja) 2008-01-10
NZ511931A (en) 2004-01-30
RU2003112447A (ru) 2005-02-20
CN1329620A (zh) 2002-01-02
TWI327069B (en) 2010-07-11
TW201041590A (en) 2010-12-01
HUP0104574A3 (en) 2002-09-30
AU762012B2 (en) 2003-06-19
BR9915961A (pt) 2001-08-21
CA2353574C (en) 2012-05-08
NO20012786L (no) 2001-07-20
EP1137667B1 (en) 2004-11-17
EP1137667A2 (en) 2001-10-04
DE69922043D1 (de) 2004-12-23
AU1973600A (en) 2000-06-26
NO20032093D0 (no) 2003-05-09
KR20040053220A (ko) 2004-06-23
PL349468A1 (en) 2002-07-29
NO20032093L (no) 2001-07-20
NO319128B1 (no) 2005-06-20
PT1137667E (pt) 2005-02-28
CZ295890B6 (cs) 2005-11-16
IL143346A0 (en) 2002-04-21
ES2230912T3 (es) 2005-05-01
JP2004131473A (ja) 2004-04-30
NZ527241A (en) 2004-12-24
PL202367B1 (pl) 2009-06-30
TWI327150B (en) 2010-07-11
KR20010080713A (ko) 2001-08-22
ATE282635T1 (de) 2004-12-15
TW200302229A (en) 2003-08-01
TWI352599B (en) 2011-11-21
CZ295889B6 (cs) 2005-11-16
US20090197802A1 (en) 2009-08-06
CN1495198A (zh) 2004-05-12
NO20012786D0 (no) 2001-06-06
CA2353574A1 (en) 2000-06-15
JP2005132845A (ja) 2005-05-26
US6903186B1 (en) 2005-06-07
US7977455B2 (en) 2011-07-12
EP2322545A1 (en) 2011-05-18
WO2000034331A3 (en) 2000-11-16
WO2000034331A2 (en) 2000-06-15
SG125915A1 (en) 2006-10-30
US8138305B2 (en) 2012-03-20
TW200626613A (en) 2006-08-01
CZ295768B6 (cs) 2005-10-12
JP4620444B2 (ja) 2011-01-26
CZ295891B6 (cs) 2005-11-16
US7268213B2 (en) 2007-09-11
TWI255271B (en) 2006-05-21
TW200422300A (en) 2004-11-01
RU2288232C9 (ru) 2007-04-20
KR100452417B1 (ko) 2004-10-12
KR100511855B1 (ko) 2005-09-02
HK1037196A1 (en) 2002-02-01
KR20050037004A (ko) 2005-04-20
JP3702181B2 (ja) 2005-10-05
US7235628B2 (en) 2007-06-26
US20080108566A1 (en) 2008-05-08
CZ294029B6 (cs) 2004-09-15
JP3934092B2 (ja) 2007-06-20
JP2002531578A (ja) 2002-09-24
RU2288232C2 (ru) 2006-11-27

Similar Documents

Publication Publication Date Title
RU2214418C2 (ru) Аналоги glp-1
ATE177114T1 (de) Polypeptide und daraus hergestellte, gegen hiv wirksame substanzen
DK0741716T3 (da) Delta12,13-Iso-taxolanaloger, antineoplastisk anvendelse og farmaceutiske præparater indeholdende dem
IL112112A (en) Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
RU97118224A (ru) Соединения и композиции для доставки активных агентов
SE8300736D0 (sv) Novel pharmacologically active compounds
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
RU95108326A (ru) Уплотнительный элемент
EA200000789A1 (ru) N-[(замещенное пятичленное ди- или триазадиненасыщенное кольцо) карбонил] гуанидиновые производные для лечения ишемии
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
NO20050066L (no) Pegylert T20 polypeptid
BR9910639A (pt) Drogas anti-angiogênicas compreendendo peptìdeo
DE69531098D1 (de) Piperidine und pyrrolidine
MX9704738A (es) Analogos de peptido p277 y composiciones farmaceuticas que los contienen, metodo de diagnostico de diabetes mellitus dependiente de la insulina y uso de los mismos.
DK0633763T3 (da) Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
DE69420872D1 (de) Hgh enthaltende pharmazeutische zubereitungen
ES2103493T3 (es) Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo.
BG103677A (en) Solid mixtures based on sulphonylcarbamides and adjuvants
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
RU2227144C2 (ru) Замещенные триптофансодержащие дипептиды с холецистокининонегативной или холецистокининопозитивной активностью
FI964448A0 (fi) Uusi biologisesti aktiivinen peptidi ja sen valmistus
ATE53024T1 (de) Biologisch aktive substanz, girolline genannt, extrahiert aus dem schwamm pseudaxinyssa cantharella, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR890701118A (ko) 혈소판 감소증 예방 및 치료제

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20131208